Early Access — free while we kick the tires
EdgarHawk

Shih Alvin

Director

Director
1 filing analyzed · 1 company · Latest 2025-09-15

Companies

Company Buys Sells Direction
ZEVRA THERAPEUTICS, INC. ZVRA 1 0 Net buying

Activity

September 2025
medium
Buy
20,000 shares
$157,800
Significance 5/10

Director Shih Alvin purchases 20.0K shares of ZVRA at $7.89; stock now at $7.23, down 43.5% from 52-week high.

Director Shih Alvin's purchase of 20,000 shares at $7.89 represents his first entry into ZVRA holdings. The stock has declined significantly since the transaction date, trading at $7.23 (down 23.3% over 30 days and 17.9% over 90 days) and 43.5% below its 52-week high of $12.79. The company's fundamentals present a complex picture: it reported net income of $74.7M against quarterly revenue of $25.9M, yet faces negative full-year results with annual revenue declining 14.0% year-over-year and a P/E ratio of 144.60 suggesting distressed valuation metrics. An insider director establishing a new position during a sustained downtrend warrants attention to the disclosed reasoning and broader context, particularly given the company's recent profitability challenges despite headline quarterly earnings.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access